BPC-157 Peptide: Everything You Need to Know

Peptide Guides

What is BPC-157?

Much of the human body is built from protein. Muscle, skin and the gut lining are all largely protein. Every protein is made of small units called amino acids, joined together in a chain. A peptide is a short chain of the same units.

BPC-157 is a peptide made in a laboratory. Its chain is 15 amino acids long, which is why research papers call it a pentadecapeptide, from the Greek for fifteen.

The order of the amino acids in a chain is called the sequence, and the sequence is what makes each peptide what it is. BPC-157's sequence is copied from a small section of a much larger protein found in human gastric juice, the acidic fluid in the stomach. It does not exist in nature on its own. Our introduction to peptides covers what peptides are and how they are made.

One property sets it apart from most peptides. Stomach acid destroys almost every peptide quickly. BPC-157, having been derived from a stomach protein, is unusually stable in gastric juice. That stability is a large part of why researchers took an interest in it, and why so much of the discussion around it concerns swallowed and injected forms.

Where BPC-157 came from

BPC-157 was first described in the early 1990s by a research group at the University of Zagreb in Croatia. The group was studying why the stomach lining does not digest itself despite sitting in acid, and proposed that a protective protein in gastric juice was responsible. They named it Body Protection Compound, which is what BPC stands for. BPC-157 is the fragment of that protein they identified as the active section and then produced synthetically.

The same group has driven most of the research on the compound for over thirty years.

BPC-157 has never been developed into a medicine. No pharmaceutical company owns it, no patent protects it, and no marketing authorisation, the licence a medicine needs before it can be sold as one, has ever been applied for. It has spent three decades as a research compound.

What does BPC-157 do?

Everything known about what BPC-157 does comes from studies in animals and in cells. No finding below comes from a human trial, because none exists.

In rats, BPC-157 has been reported to speed the healing of a wide range of injuries. The most studied areas are the gut, where it was first investigated as an anti-ulcer compound, and the musculoskeletal system, meaning tendons, ligaments and muscle. Studies from the Zagreb group have also reported effects on damaged nerves, blood vessels and the spinal cord. In one 2019 study, rats given a single injection of BPC-157 after a crush injury to the spinal cord recovered tail function while untreated rats did not.¹

Researchers have proposed several mechanisms from this animal and cell work. BPC-157 appears to promote angiogenesis, the growth of new blood vessels, which injured tissue needs to heal. It appears to increase the activity of fibroblasts, the cells that build collagen, the main structural material of tendons and skin. And it appears to interact with the body's nitric oxide system, which helps control blood flow and inflammation.²

Every sentence above describes findings in animals or cells. Whether any of it happens in a human body has not been established, because the studies that would establish it have never been run.

BPC-157 benefits and what the evidence shows

The benefits claimed for BPC-157 include faster tendon healing, muscle recovery, gut repair and joint pain relief. These claims take real findings from rat studies and restate them as if they were established human outcomes.

The claims are not invented from nothing. Rat studies genuinely did report faster tendon healing, protection of the gut lining, and improved recovery from muscle injury. What the claims leave out is the species, and the fact that most compounds that help rodents fail when properly tested in people. Our guide to animal versus human research explains why that transfer fails so often.

Two reviews published in 2026 examined the peptides marketed for recovery and performance, BPC-157 among them. Both reached the same conclusion. The animal results are promising, and the human evidence is scarce, weak or absent.^3,4 A 2026 primer written for orthopaedic surgeons put it directly, describing BPC-157's reported benefits as largely unvalidated in human trials.⁵

In rats, the effects are repeatedly reported across many injury types. In humans, they have never been demonstrated in a controlled study, because no controlled study has been run.

The BPC-157 research record

Roughly 190 papers on BPC-157 are indexed on PubMed, the main database of medical research. Almost all of it is animal and laboratory work. Not one paper is indexed as a clinical trial of any phase. For comparison, a compound that becomes a medicine typically accumulates dozens of registered trials on its way to a licence.

The research is also unusually concentrated. A large share of the animal literature comes from the Zagreb group that discovered the compound, including the major reviews of its healing effects.⁶ Independent replication, different laboratories reaching the same result, is how science checks itself, and BPC-157 has less of it than the paper count suggests. Our guide to reading a peptide study covers how to weigh points like this.

None of this means the animal findings are false. It means the evidence is narrower than it looks from a distance, and that the step that turns interesting animal findings into medical knowledge, the controlled human trial, is still missing entirely.

The complete human evidence for BPC-157

The published human evidence on BPC-157 is three small reports, covering thirty people in total, all from a single private clinic in Florida, all in one journal.

The first, from 2021, contacted 16 patients by phone after knee injections and reported that most recalled improvement.⁷ The second, from 2024, treated 12 women with bladder pain and reported symptom relief, with no comparison group.⁸ The third, from 2025, gave intravenous BPC-157 to 2 people and reported no changes in their blood tests.⁹

None of these had a control group, so none can distinguish the compound's effect from expectation, natural recovery or chance. The orthopaedic primer mentioned above described this human evidence as limited by significant methodological flaws and a lack of controls.⁵ That is the entire human record. Everything else written about BPC-157 in people is taken from rat studies.

The forms BPC-157 is sold in

Research-grade BPC-157 is supplied as a freeze-dried powder in sealed vials, labelled by weight of peptide. Our guide to reconstituting peptides covers how a solution of known strength is prepared from it in a laboratory setting.

Capsules, tablets and nasal sprays are also marketed online. The gastric stability that makes oral BPC-157 plausible in principle is real, but stability in stomach acid is not the same as absorption into the body, and the animal research used injected and directly applied forms far more often than swallowed ones. A separate guide on oral forms is planned as part of this series.

Because the compound sits outside the medicines system, no regulator checks what any BPC-157 product contains. Purity and identity depend entirely on the supplier's testing. Each batch of research-grade BPC-157 supplied through this site is independently tested for purity before listing, and the dated certificate of analysis is published for download.

Is BPC-157 legal?

In the UK, BPC-157 is not a licensed medicine, not an approved food supplement, and not a controlled drug. Supplying it for laboratory research is lawful. Selling or advertising it for people to use is a criminal offence, and possessing it is not an offence.

In 2026, a US advisory committee voted to recommend BPC-157 for a list of substances American compounding pharmacies may work with. That vote was advisory, nothing has been added to any list, and it changed nothing in the UK. The full picture, including the US position and buying considerations, is in our guide to whether BPC-157 is legal in the UK.

Is BPC-157 safe?

The studies that establish a safety profile have never been done in humans, so no reliable answer exists. Animal studies report no toxicity signal, and the three small human reports noted no adverse events, but thirty people in uncontrolled reports cannot establish safety, and were not designed to detect harm.

Unknown is not the same as safe, and it is also not the same as dangerous. It is unknown. Our guide to BPC-157 side effects sets out what is and is not known, including the cancer question and whether effects differ between men and women.

Common questions about BPC-157

Is BPC-157 FDA approved?

No. BPC-157 is not approved as a medicine by the FDA, the MHRA or any other regulator, and no application for approval has ever been made. The 2026 US advisory vote concerned pharmacy compounding rules, not approval, and has not taken effect.

Does BPC-157 work?

In rats, across many injury models, studies have repeatedly reported that it does. In humans, the question has never been properly tested. Three uncontrolled reports on thirty people cannot establish that a compound works. Our guide to whether BPC-157 works examines the evidence in detail, and our record of BPC-157 clinical trials and human studies lists every human study and registered trial individually.

Is BPC-157 banned in sport?

Yes. The World Anti-Doping Agency prohibits BPC-157 at all times, in and out of competition, and anti-doping laboratories can detect it. Athletes in tested sports should treat it as prohibited.

Is BPC-157 the same as TB-500?

No. They are different peptides with different sequences and different origins, often discussed together because they appear in the same animal research areas and are sold by the same suppliers. TB-500 is a fragment of a naturally occurring protein called thymosin beta-4. BPC-157 comes from a stomach protein.

Specification and supply

BPC-157 supplied through this site is freeze-dried (lyophilised) powder, purity-tested by HPLC with identity confirmed by mass spectrometry, with a dated certificate of analysis per batch. The full range and specifications are listed under research peptides.

Supplied for laboratory research use only. Not for human consumption.

References

1. Perovic D, Kolenc D, Bilic V, et al. Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats. J Orthop Surg Res. 2019. DOI
2. Yuan C, Demers A, Silva-Ortiz V, et al. From regeneration to analgesia: the role of BPC-157 in tissue repair and pain management. Int J Mol Sci. 2026. DOI
3. Mendias CL, Awan TM. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Med. 2026. DOI
4. Tewari K, Liu TP, Im C, et al. Peptide supplements and their therapeutic applications in sports medicine. Am J Sports Med. 2026. DOI
5. Mayfield CK, Bolia IK, Feingold CL, et al. Injectable peptide therapy: a primer for orthopaedic and sports medicine physicians. Am J Sports Med. 2026. DOI
6. Matek D, Matek I, Japjec M, et al. Tendon, ligament, and muscle injury therapy perspectives with growth factors and stable gastric pentadecapeptide BPC 157: a review. Pharmaceuticals (Basel). 2026. DOI
7. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021. PMID 34324435
8. Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med. 2024. PMID 39325560
9. Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025. PMID 40131143